Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

James Mullen

Moderated Keynote

Vicarius Pharma

George Golumbeski

Keynote Fireside Chat


Sep 04
Show Filter
7:00am - 8:00am 60 mins
Registration and Networking Breakfast
8:00am - 8:15am 15 mins
Welcome and Opening Remarks
  • John Westwood - Global Head of Life Sciences, Huron Consulting Group
8:15am - 9:00am 45 mins
Defining your BD Strategy vs. Opportunism - Consistent Corporate Vision
  • Susan Graf - Chief Business Officer, Epizyme
  • Jonathan Lanfear - Global Head, R&D Business Development, Takeda Pharmaceuticals International, Inc
  • Philippe Lopes-Fernandes - Senior Vice President, Global Head of Business Development & Alliance Management, EMD Serono, a division of Merck KGaA, Darmstadt, Germany
  • Phil McGurk - Business Development Lead, Inflammation & Immunology, Pfizer
  • Moderator Helen Ho - Vice President, Corporate Development, Blueprint Medicines

How do you balance your BD strategy while also remaining poised for unanticipated opportunity?

9:00am - 9:30am 30 mins
Moderated Keynote
  • James Mullen - Chairman, Vicarius Pharma
  • Moderator Christoph Westphal, MD, PhD - Co-Founder and Partner, Longwood Fund

Listen in as veteran biotech leader Jim Mullen shares insight from his considerable experience in the industry and hear about his new company's focus: helping small biotech do development in Europe

9:30am - 10:00am 30 mins
Networking Break
10:00am - 10:45am 45 mins
Alternative Capital Sources
  • Dee Datta - Chief Business Officer, Xoma
  • Chris Garabedian - Chairman and CEO, Xontogeny
  • Ellie McGuire - Partner, LS Polaris Innovation Fund
  • Ed Zhang - Vice President of Corporate Development, Boston Pharmaceuticals
  • Moderator Christopher de Souza - Director, Broadview Ventures

Explore the current trends in alternative financing for different stages of biotech investment, and the implications for future financing and development strategy

10:45am - 10:55am 10 mins
Spotlight Focus: Axial Biotherapeutics
  • David Donabedian, PhD - CEO, Co-Founder, Axial Biotherapeutics

Here the story behind the story from Axial CEO David Donabedian, on this 2017 Fierce 15 biotech company, including key takeaways on lessons learned 

10:55am - 11:30am 35 mins
VC Investments: Raising Capital
  • Panelist David Donabedian, PhD - CEO, Co-Founder, Axial Biotherapeutics
  • Panelist Ellie McGuire - Partner, LS Polaris Innovation Fund
  • Moderator Rich Rieger - Managing Director, Huron Life Sciences

What are the latest trends in raising capital and how are they impacting biotech investment in the US? How can choosing your partners impact your success? 

11:30am - 11:40am 10 mins
Spotlight Focus: Turnstone Biologics
  • Kris Elverum - Chief Business Officer, Turnstone Biologics

Hear from this 2017 Fierce 15 biotech winner's Chief Business Officer on a busy year and gain insight from an inside look at recent key development deals helping to shape the future. 

11:40am - 12:15pm 35 mins
Small Biotech & Pharma Partnering
  • Kris Elverum - Chief Business Officer, Turnstone Biologics
  • Micah Mackison - Senior Vice President, Corporate Development & Strategy, Assembly Biosciences
  • Torsten Mummenbrauer - Senior Vice President, Business Development & Licensing, Hookipa Pharma Inc.
  • Moderator James Kasuboski - Senior Director, Boehringer Ingelheim Venture Fund

What, when, and where, matters in partnering strategy between small biotech and pharma, discuss the different elements that need to be considered when laying out your long term commercial strategy. 

12:15pm - 1:15pm 60 mins
Networking Lunch
1:15pm - 1:45pm 30 mins
Creative Deal Structures
  • Panelist Rodolphe Clerval - CBO, Enterome
  • Panelist Kia Motesharei, PhD - Head of Business Development, Neurology and Immunology, EMD Serono, a division of Merck KGaA
  • Panelist John Quisel - Executive Vice President, Chief Business Officer, Acceleron Pharma
  • Moderator Diala Ezzeddine - President and CEO, Xiox Therapeutics

What makes a deal creative ? How does necessity lead to invention when thinking outside the box on partnerships, licensing, collaboration and other business development deals in biotech and pharma?

1:45pm - 2:15pm 30 mins
When to Think Commercial?
  • Jean-Sebastien Cleiftie - CBO, Erytech Pharma
  • Jennifer King - VP Business Development, Intellia Therapeutics
  • Moderator Marc Tomassi - Managing Director, Huron Life Sciences

Is there ever a time to not think commercial?  Identify the questions that need to be asked when developing & implementing  commercial strategy. 

2:15pm - 2:45pm 30 mins
Keynote Fireside Chat
  • George Golumbeski - President, Grail
  • Moderator Arthur Hiller - CEO, Antyllus Therapeutics
2:45pm - 3:15pm 30 mins
Networking Break
3:15pm - 3:45pm 30 mins
The Impact of Novel Modalities: Deal-Making in the Era of Disruptive Technologies
  • Christopher Guiffre - Chief Financial Officer & Chief Operating Officer, Pear Therapeutics
  • Vincent Hennemand - SVP Strategy, Corporate and Business Development, Akili Interactive Labs
  • Moderator David Moller - CSO, Sigilon Therapeutics

How might future and emerging tech modalities impact biotech deal-making?

3:45pm - 4:15pm 30 mins
Fireside Chat: Academic Partnering - New Models for Mutually Beneficial Collaborations
  • Karen Heidelberger - Partner, Deerfield Management
  • Lesley Solomon - SVP Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute
  • Moderator James Zanewicz - Chief Business Officer, Tulane University School of Medicine
4:15pm - 4:45pm 30 mins
The Future of Deal-Making & Partnerships: 2018 and Beyond
  • Lawrence Klein - Head of Business Development & Strategy, CRISPR Therapeutics
  • Elizabeth O'Day - CEO & Founder, Olaris Therpeutics
  • Shobha Parthasarathi - Vice President, Strategic Alliances and Business Development, Harrington Discovery Institute
  • Moderator John Hallinan - Chief Business Officer, MassBio

A new twist on future predictions in deal making- including a closer look at disruptive technology and the impact of data on business development deals in biopharma

4:45pm - 5:00pm 15 mins
Closing Remarks
  • Rakhshita Dhar - Business Development, Roche
5:00pm - 6:00pm 60 mins
Cocktails and Hors d'oeuvres